India's Genom Biotech plans to build plant in Ukraine

Genom Biotech, one of India’s leading pharmaceutical companies, is considering building a drug-making plant in the Ukrainian region of Sumy. The total amount of investments in the project has not yet been disclosed but, according to some Ukrainian analysts, it might be in the range of $50 million to $70 million.

The company is currently looking for land for the construction of the factory, which area is expected to be built on around 5 hectares. The setting u of the plant is expected to help Genom Biotech to start a massive expansion of the Ukrainian and Russian pharmaceutical markets as well as to organize supplies to the European Union and Asian countries.

Genom Biotech has already had its own subsidiary in Ukraine, which operates as an importer of the company’s products from abroad, in particular from India. At present the Ukrainian range of the company is comprised of more than 100 products, among them are such popular as Sigan, Metrozol and Koldflyu. There is a possibility that the production of some of these drugs might be introduced at the company’s new Ukrainian plant.